Draig Therapeutics, a clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric ...

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...

QuantumCell has licensed AlzeCure Pharma’s Alzheimer’s disease platform and lead asset for $12 million upfront in a heavily back-loaded deal that bags a potentially symptom-relieving drug candidate on ...

Merck & Co. has nixed the phase 2 study of a potential Alzheimer’s disease medicine after the drug underwhelmed in an interim analysis, marking another blow for the pharma’s struggling partner ...

IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26FDA’s decision follows ...

Neurocrine Biosciences, Inc. stays a Buy as Ingrezza, Crenessity, and Vykat drive 44% revenue growth; see valuation, patents ...

Hikma Pharma launches anti-seizure medication Xcopri in the UAE: London Tuesday, July 7, 2026, 15:00 Hrs [IST] Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, ...

Despite financial hurdles, Addex Therapeutics Ltd (ADXN) makes significant strides in drug development and strategic positioning.

Scientists at the University of California San Diego have uncovered how genetic mutations cause a rare group of inherited neuromuscular disorders and identified promising new strategies to correct ...

I have had the honor of writing small health-related articles for our wonderful paper for almost 20 years. If there are more ...

Pulmonary arterial hypertension (PAH) is a rare, progressive disease of the precapillary pulmonary arteries, characterized by ...